Zobrazeno 1 - 10
of 269
pro vyhledávání: '"John E. Scott"'
Autor:
Seoyeon Bok, Dong Yeon Shin, Alisha R. Yallowitz, Mark Eiseman, Michelle Cung, Ren Xu, Na Li, Jun Sun, Alfred L. Williams, John E. Scott, Bing Su, Jae-Hyuck Shim, Matthew B. Greenblatt
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
Neurofibromatosis type I (NF1) is characterized by prominent skeletal abnormalities mediated in part by aberrant ERK pathway activation due to NF1 loss-of-function. Here, the authors report the MEKK2 is a key mediator of this aberrant ERK activation
Externí odkaz:
https://doaj.org/article/1bdc5e8883dd407b82aab19c4cfb975b
Publikováno v:
MethodsX, Vol 9, Iss , Pp 101927- (2022)
PTEN is a well-known tumor suppressor that is inactivated or suppressed at a high frequency in cancer. We sought an assay to screen compounds for ones that differentially inhibited proliferation or induced cytotoxicity in PTEN mutated cancer cells. W
Externí odkaz:
https://doaj.org/article/d4ebe48383f1404f8517558a0620731e
Autor:
Ladislas Robert
Publikováno v:
Pathologie Biologie. 60:334-335
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9d1a53bb659f77ff79dd9e392a4e12a
https://doi.org/10.1016/j.patbio.2012.09.001
https://doi.org/10.1016/j.patbio.2012.09.001
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stephen T.C. Wong, Li-An Yeh, John E. Scott, Hong Zhao, Alexandria T. Phan, Alfred L. Williams, Syed Ahmad, Xiaoping Zhu, Timothy Liu, Ren Kong
PDF file - 506KB, Supp. Fig. S1 2D structures of Amoxapine, Amoxapine's metabolites, Loxapine, and the previous reported potent GUS inhibitors - Inhibitor 1 and 2. Suppl. Fig. S2 The initial structures (left panel, Before MD) and the last snapshots (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49a225afd9a133bef2e1e79e54383b80
https://doi.org/10.1158/1078-0432.22454507
https://doi.org/10.1158/1078-0432.22454507
Autor:
Stephen T.C. Wong, Li-An Yeh, John E. Scott, Hong Zhao, Alexandria T. Phan, Alfred L. Williams, Syed Ahmad, Xiaoping Zhu, Timothy Liu, Ren Kong
Purpose: Irinotecan (CPT-11) induced diarrhea occurs frequently in patients with cancer and limits its usage. Bacteria β-glucuronidase (GUS) enzymes in intestines convert the nontoxic metabolite of CPT-11, SN-38G, to toxic SN-38, and finally lead to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92418d4a91128658e5adf62c7b2a8f9a
https://doi.org/10.1158/1078-0432.c.6522764.v1
https://doi.org/10.1158/1078-0432.c.6522764.v1
Publikováno v:
Trends in Applied Sciences Research. 15:242-252
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6b7b2ba1ed3e0e8a1db66d638822b03
https://doi.org/10.3923/tasr.2020.242.252
https://doi.org/10.3923/tasr.2020.242.252
Autor:
Mark Eiseman, Matthew B. Greenblatt, Jae-Hyuck Shim, Jun Sun, Alisha R. Yallowitz, Dong Yeon Shin, Na Li, Michelle Cung, Bing Su, Seoyeon Bok, Ren Xu, Alfred L. Williams, John E. Scott
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
Neurofibromatosis type I (NF1) is characterized by prominent skeletal manifestations caused by NF1 loss. While inhibitors of the ERK activating kinases MEK1/2 are promising as a means to treat NF1, the broad blockade of the ERK pathway produced by th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f0f24f190ae8316acceb682d204a810
http://europepmc.org/articles/PMC7658220
http://europepmc.org/articles/PMC7658220
Autor:
John E. Scott, Hamzah Kharabsheh
Publikováno v:
Biochem Biophys Res Commun
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. CoA synthase (CoAsy) is a bifunctional enzyme, encoded by the COASY gene, which catalyzes the last two steps of CoA biosynthesis. COASY has been reporte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e362a4866e13f4c9604cdf41225d12
https://pubmed.ncbi.nlm.nih.gov/32828275
https://pubmed.ncbi.nlm.nih.gov/32828275
Publikováno v:
SLAS Discov
Triple-negative breast cancer (TNBC) is a very aggressive form of breast cancer with few molecularly targeted therapies. We used a novel unbiased approach to identify higher-order synergistic or enhancer combinations of marketed kinase inhibitor drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d32adfba844af8a651c57abd4a3aa58
https://pubmed.ncbi.nlm.nih.gov/32441190
https://pubmed.ncbi.nlm.nih.gov/32441190